Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408039 · ClinicalTrials.gov registry record
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 1,331
- Enrollment target
NCT05408039 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 1,331 participants.
The verdict
NCT05408039 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 1,331 participants
- Enrollment target
Study Summary
This study aims to increase the understanding of Hyperkalemia (HK) management, treatment patterns, and the treatment decision-making process for the management of patients with HK over a period of up to 12 months. The generation of real-world evidence (RWE) to understand the treatment management decision rationale and to prospectively describe patient characteristics, treatment management patterns among patients with HK is of importance to improve adherence to guidelines and improve patient care. The primary objective: • Describe HK management decisions, their rationale and treatment expectations. The secondary objective: • Describe baseline characteristics and longitudinal clinical variables in patients with HK. The exploratory objective: • Describe patient awareness and satisfaction with their HK treatment management across the study period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,331 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2024-12-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05408039
The ClinicalTrials.gov registry entry for NCT05408039 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05408039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05408039 about?
NCT05408039 is a clinical study titled "Tracking Treatment Pathways in Adult Patients With Hyperkalemia.". This study aims to increase the understanding of Hyperkalemia (HK) management, treatment patterns, and the treatment decision-making process for the management of patients with HK over a period of up to 12 months. The generation of real-world evidence (RWE) to understand the treatment management dec...
What is the current status of trial NCT05408039?
This trial is currently completed. The enrollment target is 1,331 participants. The study started on 2022-07-14. Estimated completion is 2024-12-19.
Who is sponsoring clinical trial NCT05408039?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.